Aurora kinase A drives non-canonical YAP1/TAZ crosstalk to sustain primary resistance to anti-EGFR therapies in colorectal cancer

Anti-epidermal growth factor receptor (EGFR) therapies are the most recommended first-line treatment for RAS/RAF wild-type unresectable metastatic colorectal cancer (CRC) according to the European Society for Medical Oncology guidelines. However, primary resistance renders this treatment ineffective...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Anxo Rio-Vilariño, Ana Garcia-Bautista, Aiora Cenigaonandia-Campillo, Pedro A. Mateos-Gomez, Laura Garcia-Garcia, Marina I. Schlaepfer, Laura Garcia-Hernandez, Laura del Puerto-Nevado, Oscar Aguilera, Natalia Baños, Pablo Minguez, Víctor Manuel Castellano, Jesús Garcia-Foncillas, Arancha Cebrian
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2025-09-01
Σειρά:	Molecular Therapy: Oncology
Θέματα:	anti-EGFR Aurora kinase A cancer stem cells cetuximab drug resistance metastatic colorectal cancer
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2950329925001018
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!